Mereo BioPharma Group Plc (MPH) was formed in the year 2015. It is a speciality biopharmaceutical company which develops novel medicines for the treatment of rare and speciality diseases. The company's pipeline products include BPS-804, which is used for the treatment of brittle bone syndrome; and BCT-197, an orally active p38 MAP kinase inhibitor developed for acute exacerbations of chronic obstructive pulmonary disease.
Financial Highlights – FY2018
Operating loss for FY18 stood at £35.20 mn as compared to the operating loss of £45.30 mn in FY17 and before tax loss stood at £37.30 mn versus the loss of £46.95 mn in FY 17. The reported basic and diluted loss per share stood at £0.45 versus loss of £0.56 in FY17. Group’s interest-bearing loans and borrowing declined by 22% to £14.64 mn from £18.81 mn in FY17.
The group’s reported net cash flow on account of operating activities was an outflow of £23.13 mn as compared with the outflow £32.14 mn during the previous financial year. Net cash generated from investing activities stood at £0.25 mn, primarily on account of interest earned of £0.28 mn, against an outflow of £3.74 mn reported last year. Net cash flow on account of financing activities was an outflow £2.07 mn as compared with the inflow of £33.74 mn in FY17. The net change in cash and cash equivalents for FY18 was an outflow of £24.95 mn as compared with the outflow of £2.14 mn during FY17.
During the past financial year, the drug maker has patented 112 adults in Phase2 dose-ranging study with the initial data expected in the second quarter of FY19.
Chairman & CEO’s statement
Our strategy in line with the aim to create a portfolio of rare disease products acquired from large pharmaceutical companies and to develop these products through an approval from the concerned regulator and subsequent commercialisation.
Stock Performance – 1 Year
Daily price chart (as on May 01, 2019), before the market close. (Source: Thomson Reuters)
At the time of writing (as on May 01, 2019, at 08:30 AM GMT), shares of MPH were quoting at GBX 112.5 and declined by 2.50 points or 2.22% against the previous day close. During the past one-year, shares have registered a 52w high of GBX 325 and a 52w low of GBX 105.
At the current market price, as quoted in the price chart, shares were trading considerably below the 30-day, 60-day and 200-day simple moving average. On a yearly basis, the stock has delivered a negative return of 65.38%.
The outstanding market capitalisation of the company stood at £ 103.23 mn, which ranks it among the small-cap categories listed on the London Stock Exchange.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.
